PERJETA is indicated for use in combination with Herceptin® (trastuzumab) and chemotherapy for the neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer (EBC).1
Multiple studies have evaluated the efficacy and safety of PERJETA + Herceptin-based neoadjuvant therapy in patients with HER2+ breast cancer.
HER2=human epidermal growth factor receptor 2.
*Patients should discontinue treatment before 1 year if they experience disease recurrence or unmanageable side effects.
Patients who begin PERJETA and Herceptin in the neoadjuvant setting should receive 3-6 cycles before surgery and should continue treatment after surgery, every 3 weeks, to complete 1 year (up to 18 cycles).
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.